- During a declared emergency, a pharmacy dispenses EUA-authorized medications. After the emergency declaration ends, the EUA is terminated. Which of the following best describes the pharmacy's post-termination obligations?
Answer: Retain EUA records per specified retention requirements despite EUA termination.
EUA dispensing records must be retained per the applicable retention requirements even after the EUA terminates. The termination of an EUA does not eliminate recordkeeping obligations for the dispensing that occurred under the EUA. A correctly identifies this continuing obligation. B is incorrect because records cannot be discarded upon EUA termination; retention requirements continue. C is incorrect because 90 days is not a standard EUA records retention period. D is incorrect because records do not automatically transfer to the FDA; they remain with the pharmacy subject to applicable retention requirements.
- An EUA authorizes a novel antiviral for treating a new viral disease. The EUA conditions require the pharmacy to maintain a log of all patients who received the product, including patient identifiers and lot numbers. A pharmacist asks whether this patient-level tracking is required even if it conflicts with the pharmacy's existing privacy policies. Which of the following best analyzes this situation?
Answer: EUA tracking requirements are mandatory and must be followed, while ensuring compliance with applicable privacy laws.
EUA-required tracking obligations are legally binding conditions of authorization established by the FDA. HIPAA and applicable privacy laws continue to apply and the pharmacy must handle records in compliance with them, but they do not eliminate the EUA-mandated tracking obligation. D correctly identifies this analysis. A is incorrect because the pharmacy cannot decline EUA-required tracking based on internal privacy policies; EUA conditions are legally binding. B is incorrect because EUA tracking requirements imposed as conditions of authorization are mandatory, not purely voluntary; patient consent to being tracked does not eliminate the pharmacy's legal obligation to maintain required records. C is incorrect because EUA conditions are enforceable obligations regardless of whether an FDA inspection occurs.
- A pharmacist dispensing EUA-authorized medications during a public health emergency receives a call from a patient who has started the treatment and wants to discontinue it after reading an article claiming the treatment is ineffective. Which of the following best describes the pharmacist's obligations?
Answer: The pharmacist should provide information and refer the patient to their prescriber for further discussion.
The pharmacist should address the patient's concerns with accurate information, refer to the prescriber for clinical management, and respect the patient's right to accept or refuse as provided in the EUA framework. D correctly balances these obligations. A is incorrect because the pharmacist should not pressure a patient to continue; the patient's right to refuse is a key EUA element. B is incorrect because patients may discontinue EUA treatments; the right to accept or refuse is part of the framework. C is incorrect because the pharmacist should not validate unverified news claims and instead should provide accurate information based on current FDA guidance.
- A pharmacist is asked by a patient whether the EUA-authorized treatment she is receiving is the same as an FDA-approved drug. Which of the following is the most accurate response?
Answer: EUA authorization is not the same as full FDA approval; it allows use based on preliminary evidence during emergencies, without complete clinical trial data.
The distinction between EUA authorization and full FDA approval is meaningful and must be accurately communicated to patients. EUA authorization is based on available evidence suggesting benefits outweigh risks during an emergency, without the complete clinical trial data required for full approval. The Fact Sheet specifically exists to disclose this distinction and the pharmacist should support patient understanding. A correctly describes both the distinction and the pharmacist's role. B is incorrect because EUA authorization does not involve the same level of FDA review as full approval and the two are not equivalent in approval status; equating them would mislead the patient. C is incorrect because transparency about the EUA status is required by the Fact Sheet; the pharmacist should facilitate patient understanding. D is incorrect because EUA authorization is not the same as full FDA approval even for the specific emergency indication.
- A state requires pharmacists to complete a training program before dispensing EUA-authorized vaccines. No federal EUA requirement mandates this training. Which of the following best analyzes the state requirement?
Answer: The state training requirement is valid if it does not conflict with federal EUA conditions.
FDA guidance acknowledges that EUA terms and conditions can preempt state laws that impose requirements that conflict with or are different from the EUA conditions within the EUA's scope. Where a state requirement does not conflict with EUA conditions -- such as a training program for pharmacists that is additive rather than contrary to EUA requirements -- the state requirement may stand. B correctly identifies this nuanced state-federal relationship. A is incorrect as a sweeping preemption statement; not all state pharmacy practice requirements are preempted by EUAs, only those that conflict with EUA conditions within the EUA's scope. C is incorrect because the state requirement expressly applies to dispensing in the stem; its application is not limited to administration. D is incorrect because state training requirements are not automatically waived during declared emergencies.
- During a declared public health emergency, a pharmacy asks how FDA addresses compounding needs that fall outside normal 503A and 503B requirements. Which of the following best describes FDA's approach?
Answer: FDA may issue guidance allowing temporary modifications to 503A and 503B compounding requirements during emergencies, distinct from formal EUAs.
During declared public health emergencies, FDA may issue emergency guidance, interim policies, or enforcement discretion that temporarily modifies or relaxes certain 503A and 503B compounding requirements to address supply needs. This authority is separate from the formal EUA framework under Section 564, which authorizes medical products (whether approved or unapproved) for emergency use and does not itself directly govern pharmacy compounding under the 503A/503B framework. Pharmacies seeking to compound during an emergency should consult current FDA guidance and enforcement discretion policies. C correctly describes this distinction. A is incorrect because formal EUAs are not issued directly to individual compounding pharmacies; FDA addresses compounding emergencies through guidance and enforcement discretion. B is incorrect because FDA does have authority to issue emergency guidance affecting compounding requirements. D is incorrect because FDA does not automatically waive all 503A and 503B requirements; any modifications are made through specific guidance or policies.
- A pharmacist is dispensing an EUA-authorized antiviral to a patient whose insurance does not cover EUA medications. Which of the following best describes the pharmacist's obligations regarding EUA disclosure?
Answer: The pharmacist must provide the FDA Fact Sheet for Recipients regardless of insurance coverage.
The obligation to provide the EUA Fact Sheet is not conditioned on insurance coverage. All patients receiving EUA-authorized products must receive the required Fact Sheet regardless of payment source. B correctly identifies this unconditional obligation. A is incorrect because insurance status does not waive the EUA disclosure requirement. C is incorrect because disclosure is proactive and mandatory, not contingent on patient inquiry. D is incorrect because EUA disclosure cannot be deferred; it must be provided at the time of dispensing.
- May an EUA be issued for a product that already has full FDA approval for a different indication?
Answer: Yes, an EUA can be issued for an approved product if used for a new, unapproved indication.
EUAs may be issued for unapproved uses of already-approved products. For example, a fully approved antiviral might receive an EUA for use against a novel pathogen during a public health emergency, applying the EUA risk-benefit standard to the new indication. A correctly identifies this authority. B is incorrect because EUAs are not limited to completely unapproved products; they can apply to approved products being used for new indications. C is incorrect because prior approval for a different indication does not preclude an EUA for a new indication; the EUA and the existing approval coexist. D is incorrect because withdrawal of an existing NDA or BLA is not required for an EUA to cover a different indication.
- Under Section 564 of the FDCA, which of the following best describes the authority under which the FDA may issue an Emergency Use Authorization (EUA)?
Answer: The FDA may issue an EUA during a declared public health or military emergency when benefits outweigh risks.
Under FDCA Section 564, the FDA may issue an EUA following one of three emergency declarations or determinations: a public health emergency declaration by the Secretary of HHS, a material threat determination by the Secretary of Homeland Security, or a military emergency or threat determination by the Secretary of Defense. In each case, the FDA must also determine that the known and potential benefits outweigh the known and potential risks. D correctly identifies this complete authority framework. A is incorrect because a qualifying emergency declaration or determination is required; EUAs are not issued for routine drug development. B is incorrect because manufacturer requests alone do not trigger EUA authority; an emergency determination is required. C is incorrect because EUAs specifically authorize use before full clinical trials are completed, which is their key purpose.
- Under an EUA, what standard must the FDA apply when determining whether to authorize an unapproved product or an unapproved use of an approved product?
Answer: The FDA must determine benefits outweigh risks based on available scientific evidence for serious conditions.
The EUA standard requires the FDA to determine that the known and potential benefits outweigh the known and potential risks for the indicated serious condition, based on available evidence at the time -- which may be limited. A correctly identifies this risk-benefit standard. B is incorrect because Phase 2 completion is not required; EUAs may be issued with more limited data. C is incorrect because equivalence to an approved product is not the EUA standard. D is incorrect because the FDA does not require a worldwide absence of alternatives; it evaluates the risk-benefit profile of the specific product.
- A pharmacy is about to dispense an EUA-authorized product and the pharmacist realizes the Fact Sheet provided by the manufacturer is an outdated version that has since been superseded by a revised FDA-authorized Fact Sheet. Which of the following best applies?
Answer: The pharmacist must provide the most current FDA-authorized Fact Sheet before dispensing the EUA-authorized product.
Only the current, FDA-authorized Fact Sheet satisfies EUA disclosure requirements. Using a superseded version fails to provide the required disclosures and may omit important updates to safety information. The pharmacist must obtain and use the current version before dispensing. B correctly identifies this obligation. A is incorrect because an outdated Fact Sheet does not satisfy the legal requirement; it may lack critical updated information. C is incorrect because prescriber approval does not authorize use of a superseded document. D is incorrect because using an outdated version for the current prescription violates EUA conditions.
- Under an EUA, what are the recordkeeping requirements for entities that dispense EUA-authorized products?
Answer: Maintain records as specified in the EUA conditions, including product tracking and adverse event reports, for FDA inspection.
EUA conditions of authorization typically include specific recordkeeping requirements, which may include product tracking, adverse event documentation, and Fact Sheet distribution records. These must be maintained and available for FDA inspection. C correctly identifies these requirements. A is incorrect because EUA products have specific recordkeeping requirements beyond standard dispensing records. B is incorrect because records must be retained, not destroyed, when an EUA is revoked. D is incorrect because records must be retained for required periods even after EUA termination.
- A patient who received an EUA-authorized vaccine reports a potential adverse reaction to the pharmacist who administered the vaccine. Which of the following describes the reporting pathway?
Answer: The pharmacist must report the adverse event to VAERS, as required for all EUA-authorized vaccine-related adverse events.
For EUA-authorized vaccines, VAERS is the specified reporting pathway for adverse events, consistent with the NCVIA and EUA conditions. The pharmacist who administered the vaccine bears reporting obligations. C correctly identifies VAERS as the appropriate reporting pathway. A is incorrect because the administering pharmacist has a direct reporting obligation; prescriber intermediary is not required. B is incorrect because manufacturer-only reporting does not satisfy the EUA adverse event reporting requirement. D is incorrect because reporting obligations extend to serious adverse events, not only fatalities.
- What must a pharmacist do if a patient refuses to accept an EUA-authorized medication for which the EUA Fact Sheet indicates the patient has the right to accept or refuse?
Answer: The pharmacist must document the refusal and inform the patient of potential consequences as outlined in the EUA Fact Sheet.
When an EUA Fact Sheet provides the right to accept or refuse, the patient's informed decision to refuse must be respected. The pharmacist should document the refusal and inform the patient of consequences as described in the Fact Sheet. B correctly identifies this patient-centered obligation. A is incorrect because the patient's informed refusal right is a legal and ethical entitlement that cannot be overridden. C is incorrect because patient refusals are not reportable to the FDA as adverse events. D is incorrect because a prescriber cannot override a patient's informed refusal right.
- An EUA for a novel countermeasure includes conditions of authorization under FDCA Section 564(c) requiring pharmacy enrollment, patient tracking, and dispensing controls functionally similar to a risk management program. Which of the following best describes the pharmacy's obligations?
Answer: Pharmacies must comply with all EUA conditions, including enrollment, patient tracking, and dispensing controls, as these are legally binding under Section 564(c) during the emergency authorization period.
When an EUA includes conditions of authorization under FDCA Section 564(c) that impose pharmacy enrollment, patient tracking, or dispensing controls, these are legally binding requirements the pharmacy must satisfy. Unlike REMS programs under Section 505-1 -- which apply to fully approved drugs -- EUA conditions of authorization derive from Section 564 and are specific to the emergency authorization. The functional elements may be similar to REMS requirements but their legal basis is the EUA itself. B correctly identifies this obligation. A is incorrect because EUA conditions of authorization are binding under Section 564 independently of the REMS framework applicable to approved drugs. C is incorrect because conditions of authorization imposed in an EUA are mandatory requirements, not optional during emergencies. D is incorrect because EUA conditions apply to all dispensing pharmacies covered by the authorization's scope, not only hospital pharmacies.
- A hospital system is distributing EUA-authorized monoclonal antibody treatments for COVID-19 to outpatients. The system wants to use standard informed consent forms rather than the FDA-required EUA Fact Sheets. Which of the following best applies?
Answer: The FDA requires the EUA Fact Sheet for Recipients; standard consent forms cannot replace it.
The EUA conditions specifically require the FDA-authorized Fact Sheet and do not permit substitution with standard informed consent forms. The FDA-authorized document ensures required disclosures are made consistently. D correctly identifies this requirement. A is incorrect because standard consent forms are not equivalent to the FDA-authorized Fact Sheet. B is incorrect because while similar topics may be covered, the specific FDA-authorized document is required by EUA conditions. C is incorrect because there is no general EUA Fact Sheet waiver for hospital systems.
- Under an EUA, may the FDA modify, withdraw, or revoke the authorization? Under what circumstances?
Answer: Yes, if the emergency ends, criteria are unmet, or risks outweigh benefits.
The FDA retains authority to modify, withdraw, or revoke an EUA in multiple circumstances: emergency declaration ends, EUA criteria are no longer met, the product is no longer necessary, benefits no longer outweigh risks, or the product receives full approval. A correctly identifies these circumstances. B is incorrect because EUAs can be modified or revoked before clinical trials are completed. C is incorrect because court orders are not required for FDA EUA revocations. D is incorrect because there is no specific adverse event threshold percentage that automatically triggers revocation.
- A pharmacy receives a large shipment of an EUA-authorized COVID-19 treatment. Two weeks later, the EUA for this product is revoked because a study revealed the product is ineffective. Which of the following best describes the pharmacy's immediate obligations?
Answer: Cease dispensing immediately and follow FDA guidance for disposal and notification procedures.
EUA revocation terminates authorization to dispense. The pharmacy must immediately cease dispensing, notify affected patients with pending prescriptions, and dispose of remaining stock per FDA guidance. D correctly identifies this comprehensive response. A is incorrect because revocation based on ineffectiveness still terminates dispensing authority; patients should not receive unauthorized products. B is incorrect because awaiting manufacturer instructions while holding dispensible stock is too passive given the immediate dispensing cessation obligation. C is incorrect because prior payment does not authorize dispensing of a product whose EUA has been revoked.
- Under an EUA, what is the significance of a patient being informed that an EUA product is not fully FDA-approved?
Answer: Patients must be informed of the EUA status to understand the product's distinct authorization.
EUA authorization and full FDA approval are legally and scientifically distinct. EUAs are granted on available evidence without complete clinical data; this distinction must be disclosed to patients, who for some EUA products have the right to accept or refuse. D correctly identifies this significance. A is incorrect because the distinction is legally meaningful; it determines the level of evidence underlying authorization. B is incorrect because insurance coverage of EUA products is determined by individual payer policy, not EUA status. C is incorrect because EUA products may be dispensed to Medicare and Medicaid patients.
- When dispensing an EUA-authorized medication to a patient, which of the following must the pharmacist provide?
Answer: The FDA-authorized Fact Sheet for Recipients or Caregivers.
EUA requirements mandate that recipients receive an FDA-authorized Fact Sheet for Recipients or Caregivers disclosing the EUA status, known and potential benefits and risks, alternatives, and for some products the option to accept or refuse the product. B correctly identifies this obligation. A is incorrect because the standard prescription label alone is insufficient for EUA products; the Fact Sheet is an additional required disclosure. C is incorrect because the full scientific review is not required patient disclosure material. D is incorrect because enrollment in a safety registry is not universally required for all EUA products at the time of dispensing.
